Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 4-part, Open-label, Multicenter, Multinational Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic, and Exploratory Efficacy of Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension

Next Previous
Trial Profile

A 4-part, Open-label, Multicenter, Multinational Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic, and Exploratory Efficacy of Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Venglustat (Primary) ; Imiglucerase
  • Indications Gaucher's disease type I; Gaucher's disease type III
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Acronyms LEAP
  • Sponsors Sanofi Genzyme

Most Recent Events

  • 26 Mar 2025 Planned End Date changed from 30 Sep 2025 to 30 Oct 2026.
  • 26 Mar 2025 Planned primary completion date changed from 30 Sep 2025 to 30 Oct 2026.
  • 12 Sep 2023 Planned number of patients changed from 15 to 18.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top